New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma [Yahoo! Finance]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Yahoo! Finance
AUSTIN, Texas, July 26, 2024 BUSINESS WIRE Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel cell carcinoma (MCC). The full study can be found here MCC is an aggressive skin cancer with high mortality and a recurrence rate of 40% within 5 years. MRD testing using a viral antibody is recommended by the National Comprehensive Cancer Network (NCCN) , but this tumor marker is only present in 52% of patients and has several known limitations . There is an unmet need for improved MRD testing technologies that are applicable to all patients, regardless of their viral status. This prospective, multicenter, observational study included 319 patients with stage I-IV MCC. Signatera was used to assess ctDNA levels at the time of enrollment, and every 3 months d
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- What Makes Natera (NTRA) an Investment Bet? [Yahoo! Finance]Yahoo! Finance
- Natera (NTRA) Rose After Revenues And Profit Margins Beat Estimates [Yahoo! Finance]Yahoo! Finance
- Billionaire Stan Druckenmiller Is Betting On Natera, Inc. (NTRA) [Yahoo! Finance]Yahoo! Finance
- Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire
- Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
NTRA
Earnings
- 8/8/24 - Beat
NTRA
Sec Filings
- 8/16/24 - Form 4
- 8/16/24 - Form 4
- 8/15/24 - Form 144
- NTRA's page on the SEC website